VYGR - Voyager gets termination notice for Neurocrine Parkinson's collaboration

Voyager Therapeutics (VYGR) said that its partner Neurocrine Biosciences (NBIX) had given it a notice of  termination of the Parkinson’s disease portion of their collaboration agreement, effective August 2, 2021.Voyager is evaluating the complete financial impact of the termination and the future of the Parkinson’s program and said that it expects to provide a subsequent update.The Friedreich’s ataxia program and two discovery programs that are also part of the agreement with Neurocrine are not impacted, Voyager said.Voyager’s understanding is that Neurocrine’s decision to terminate the NBIb-1817 (VY-AADC) program was based on a portfolio review and prioritization of its current pipeline assets, the company said.The FDA had put a clinical hold on Voyager and Neurocrine’s RESTORE-1 trial evaluating NBIb-1817 (VY-AADC) in Parkinson's disease, the companies had disclosed in December last year.

For further details see:

Voyager gets termination notice for Neurocrine Parkinson’s collaboration